GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced the introduction of ExactechGPS® TKA PLUS, a new software application that provides orthopaedic surgeons simplified, real-time intraoperative computer guidance during total knee arthroplasty (TKA). The new application expands the ExactechGPS portfolio and complements the company’s new Truliant® Knee System which is also making its clinical debut this quarter.
Derek Amanatullah, MD, PhD, performed the first surgery using ExactechGPS TKA PLUS at Stanford University Medical Center. “I was delighted to experience how seamlessly the system integrated into my surgical workflow,” he reported. “ExactechGPS TKA PLUS allowed me to use simple guidance to achieve precision and accuracy in my cuts, which made the knee replacement case run smoothly. I believe this system is exactly what surgeons need to help them achieve more reproducible outcomes.”
ExactechGPS is a computer technology system for guided, personalized joint replacement surgery. The new TKA PLUS software application provides surgeons a simple tool to plan, guide and verify key steps of a knee replacement procedure and easily check the patient’s implant alignment. This new application expands the ExactechGPS knee software portfolio, which also includes comprehensive applications for both primary and revision knee surgery.
“The launch of TKA PLUS reiterates Exactech’s commitment to delivering a fully comprehensive knee system to the marketplace,” said Joseph Pizzurro, vice president of Knee Marketing at Exactech. “The Truliant system of new implants and instruments, combined with our ExactechGPS technology, offers orthopaedic surgeons versatility in managing total knee arthroplasty cases from primary through revision. We are encouraged by the positive responses we have received and look forward to continued momentum behind our new knee system.”
ExactechGPS has been used in more than 8,500 total knee cases in 12 countries across the globe. ExactechGPS TKA PLUS is available in pilot launch, with full availability expected in 2018.
ExactechGPS combines surgeon expertise with an advanced computer system to perform the patient’s surgery with a goal of improved accuracy and precision. Personalized for a patient’s unique bone structure and anatomy, ExactechGPS is designed to allow surgeons to decide where to remove bone and place the implant in the optimal position. Exactech first introduced ExactechGPS to surgeons in the United States for total knee arthroplasty, and has since broadened its reach to the shoulder segment. The technology has steadily gained market acceptance and worldwide reach.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.
A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.